EP 0989986 A1 20000405 - 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS
Title (en)
5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS
Title (de)
5,7-DISUBSTITIERTE 4-AMINOPYRIDO¬2,3-D PYRIMIDINE VERBINDUNGEN UND IHRE VERWENDUNG ALS INHIBITOREN DER ADENOSIN KINASE
Title (fr)
COMPOSES DE 4-AMINOPYRIDO 2,3-D PYRIMIDINE 5,7-DISUBSTITUES ET LEUR UTILISATION COMME INHIBITEURS DE L'ADENOSINE KINASE
Publication
Application
Priority
- US 9807207 W 19980414
- US 83821697 A 19970416
Abstract (en)
[origin: WO9846605A1] A method for inhibiting adenosine kinase by administering a compound having formula (I) wherein R<1> and R<2> are independently selected from H, loweralkyl, C1-C6alkoxyC1-C6alkyl, arylC1-C6alkyl, -C(O)C1-C6alkyl, -C(O)aryl, -C(O)heterocyclic or may join together with the nitrogen to which they are attached to form a 5-7 membered ring optionally containing 1-2 additional heteroatoms selected from O, N or S; R<3> is selected from the group consisting of loweralkyl, loweralkenyl, loweralkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group, heteroarylalkyl or heterocycloalkyl wherein the heteroaryl and heterocyclic groups are linked directly or indirectly by a ring carbon; R<4> is selected from the group consisting of loweralkyl, loweralkenyl, loweralkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclic group heteroarylalkyl or heterocycloalkyl; and a dashed line --- indicates that a double bond is optionally present provided that proper valencies are maintained, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, and a method of treating cerebral ischemia, epilepsy, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, a process for preparing said compounds, and compounds having the above formula wherein R<1>, R<2>, R<3> and R<4> are separately defined.
IPC 1-7
IPC 8 full level
A61K 31/519 (2006.01); A61P 9/00 (2006.01); A61P 25/00 (2006.01); A61P 43/00 (2006.01); C07D 471/04 (2006.01)
CPC (source: EP KR)
A61K 31/519 (2013.01 - EP); A61K 31/5377 (2013.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/08 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 471/04 (2013.01 - EP KR)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE
Designated extension state (EPC)
RO SI
DOCDB simple family (publication)
WO 9846605 A1 19981022; AR 012436 A1 20001018; AU 7108398 A 19981111; BG 103842 A 20000630; BR 9809055 A 20000808; CA 2286909 A1 19981022; CN 1252070 A 20000503; CO 4940446 A1 20000724; EP 0989986 A1 20000405; HU P0001434 A2 20001028; HU P0001434 A3 20010129; IL 131618 A0 20010128; JP 2001520655 A 20011030; KR 20010006509 A 20010126; NO 995036 D0 19991015; NO 995036 L 19991015; PL 336304 A1 20000619; SK 141799 A3 20000814; TR 199902455 T2 20000121; ZA 983177 B 19990122
DOCDB simple family (application)
US 9807207 W 19980414; AR P980101733 A 19980415; AU 7108398 A 19980414; BG 10384299 A 19991029; BR 9809055 A 19980414; CA 2286909 A 19980414; CN 98804151 A 19980414; CO 98020979 A 19980416; EP 98918093 A 19980414; HU P0001434 A 19980414; IL 13161898 A 19980414; JP 54408898 A 19980414; KR 19997009599 A 19991016; NO 995036 A 19991015; PL 33630498 A 19980414; SK 141799 A 19980414; TR 9902455 T 19980414; ZA 983177 A 19980415